Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets):

1. Calcium
2. Calcium and 25-hydroxy-vitamin D
3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D

The endpoints are:

• Serum vitamin D
• Parathyroid hormone
• ionized calcium
• T-lymphocyte fractions (naïve, mature, Tregs)
• Osteocalcin (bone metabolism)

Inclusion Criteria:

• male
• HIV-positive
• at least 18 years old
• receiving HiglyActiveAntiRetroviral Therapy (HAART)

Exclusion Criteria:

• hypercalcemia
• tuberculosis
• osteoporosis or other bone disease
• cancer with bone metastasis